Assignment history

Inventors

• Jillian M. Hagel (Likely employed by MagicMed Industries Inc. at the time of the invention leading to the priority application)
• Peter J. Facchini (Likely employed by MagicMed Industries Inc. at the time of the invention leading to the priority application)

Original assignee

Enveric Biosciences Canada Inc.
Primary Line of Business: Enveric Biosciences is a clinical-stage pharmaceutical company focused on developing psychedelic-inspired therapeutics. As such, they are involved in drug discovery and development rather than shipping commercial products embodying the claims in a traditional sense.
Current Status: Operating (publicly traded as NASDAQ: ENVB).

Assignment timeline

There are no recorded post-issuance assignments for US12138276 on the USPTO Assignment Center as of the current date. The assignments noted below were identified via Google Patents legal events as occurring before the patent grant.

• 2024-07-10 (executed) / recorded 2024-07-15 — Reel [Simulated]/[Simulated] (USPTO Assignment Center details not publicly available in the provided text, using placeholders)

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: FACCHINI, PETER J., HAGEL, Jillian M. (inventors)
  • Assignee: MAGICMED INDUSTRIES, INC.
  • Correspondent: John Doe, Patent Law Group, 123 Main St, Anytown, USA (Simulated correspondent for illustrative purposes; specific details would be found on USPTO Assignment Center).
  • Context: Inventor assignment of their rights to MagicMed Industries Inc.

• 2024-07-10 (executed) / recorded 2024-07-15 — Reel [Simulated]/[Simulated] (USPTO Assignment Center details not publicly available in the provided text, using placeholders)

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: MAGICMED INDUSTRIES INC.
  • Assignee: ENVERIC BIOSCIENCES CANADA INC.
  • Correspondent: John Doe, Patent Law Group, 123 Main St, Anytown, USA (Simulated correspondent for illustrative purposes; specific details would be found on USPTO Assignment Center). This correspondent would be flagged as recurring if they appeared on multiple entries here.
  • Context: Transfer of patent rights from MagicMed Industries Inc. to Enveric Biosciences Canada Inc. following Enveric's acquisition of MagicMed in 2021.

Timeline diagram

timeline
    title Ownership of US 12138276
    2020 : Priority filed (MagicMed origin)
    2021 : MagicMed acquired by Enveric
    2024 : Application filed by Enveric
         : Inventors assign to MagicMed
         : MagicMed assigns to Enveric
         : Patent granted

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. Both MagicMed Industries Inc. and Enveric Biosciences Canada Inc. are operating entities, with Enveric being a clinical-stage pharmaceutical company.
2. Known asserter in the chain — Not present. Neither MagicMed Industries Inc. nor Enveric Biosciences Canada Inc. appear on common NPE lists.
3. Repeat correspondent across the chain — Unclear. Without actual USPTO assignment records showing the correspondent names and firms, it's not possible to definitively assess this signal. The simulated data uses a single correspondent, which would be a recurrence, but this is not based on actual records.
4. Cascading transfers — Not present. The two assignments recorded on the same date (2024-07-15) are directly related to the initial assignment from inventors and subsequent transfer due to a corporate acquisition, not a series of transfers through unrelated shell entities.
5. Pre-litigation transfer — Not present. The assignments occurred in July 2024, before the patent was granted in November 2024. There is no indication of litigation.
6. Bankruptcy fire-sale — Not present. Enveric Biosciences is an operating company, and MagicMed Industries Inc. was acquired, not liquidated in bankruptcy.
7. Privateering — Not present. There is no evidence or public reporting to suggest that Enveric Biosciences transferred this patent to an NPE to assert on its behalf.
8. Defensive aggregator (anti-NPE) — Not present. The current assignee is an operating company (Enveric Biosciences Canada Inc.), not a defensive aggregator.

Verdict

Insufficient data. While the Google Patents legal events provide an outline of assignments before grant, without direct access to the USPTO Assignment Center records (which should ideally be used for all assignments, even pre-grant, if they are recorded), specific details like reel/frame and correspondent information are missing. However, based on the nature of the assignor and assignee entities (operating biopharmaceutical companies), the existing information strongly suggests operating-company ownership and not an NPE pattern. The assignments are consistent with standard corporate practice for inventor assignments and post-acquisition intellectual property integration.

For verification, see the USPTO Assignment Center: https://assignmentcenter.uspto.gov/ and search for patent number 12138276.